Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.

about

Ritonavir-boosted protease inhibitors but not cobicistat appear safe in HIV-positive patients ingesting dabigatran.Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era

P2860

Q45072858-A59315D8-9C36-426B-91DE-1681FC62E153 Q59126145-FAB2C235-AA4F-4389-A28D-63335D32C3A0

P2860

Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.

Item

http://www.wikidata.org/entity/Q38719799

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Cobicistat Versus Ritonavir: S ...... ut Some Important Differences.

@en

type

Item

label

Cobicistat Versus Ritonavir: S ...... ut Some Important Differences.

@en

prefLabel

Cobicistat Versus Ritonavir: S ...... ut Some Important Differences.

@en

P1476

Cobicistat Versus Ritonavir: S ...... ut Some Important Differences.

@en

P2093

Christine A Hughes

http://www.w3.org/2001/XMLSchema#string

Janet Wu

http://www.w3.org/2001/XMLSchema#string

Jason Seet

http://www.w3.org/2001/XMLSchema#string

P2860

Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice

Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase Inhibitors

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.

Induction effects of ritonavir: implications for drug interactions.

Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance

Warfarin-antiretroviral interactions.

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters.

P304

1008-1022

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028017717018

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alice Tseng

Elizabeth J. Phillips

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28627229

http://www.w3.org/2001/XMLSchema#string

P932

5702580

http://www.w3.org/2001/XMLSchema#string

Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.

about

P2860

P2860

Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932